33468-85-8

Usage

Uses

Used in Coordination Chemistry:
2-(2-Pyridyl)-4-trifluoromethylimidazole is used as a ligand in the coordination chemistry of transition metals. Its ability to form stable complexes with metal ions makes it a valuable component in the development of new catalysts and materials with tailored properties.
Used in Catalysis:
In the field of catalysis, 2-(2-Pyridyl)-4-trifluoromethylimidazole is employed as a catalyst or a catalyst precursor. Its presence can enhance the efficiency and selectivity of various chemical reactions, making it a promising candidate for green and sustainable chemistry.
Used in Pharmaceutical Industry:
2-(2-Pyridyl)-4-trifluoromethylimidazole is used as a building block or a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure and properties can be exploited to design and develop new drugs with improved therapeutic effects and reduced side effects.
Used in Materials Science:
In materials science, 2-(2-Pyridyl)-4-trifluoromethylimidazole is utilized as a component in the fabrication of advanced materials with specific properties. Its incorporation into polymers, coatings, or other materials can lead to enhanced performance, such as improved stability, conductivity, or responsiveness to external stimuli.
Used in Organic Synthesis:
2-(2-Pyridyl)-4-trifluoromethylimidazole is used as a valuable building block in organic synthesis. Its reactivity and functional groups make it a useful starting material or intermediate for the preparation of a wide range of organic compounds, including agrochemicals, dyes, and other specialty chemicals.

InChI:InChI=1/C9H6F3N3/c10-9(11,12)7-5-14-8(15-7)6-3-1-2-4-13-6/h1-5H,(H,14,15)

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 

Downstream Products

• 279251-08-0 2-(2-pyridyl)-1H-4-imidazolcarbaldehyde 
• 279250-91-8 2-(2-pyridyl)-4-cyano-1H-imidazole 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Synthesis, structure, and neuroprotective properties of novel imidazolyl nitrones

A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivi

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

2-Pyrazinyl-trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.